Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  

Early multidrug treatment of SARS-CoV-2 (COVID-19) and decreased case fatality rates in Honduras

Ontai et al., Epidemiology International Journal, doi:10.23880/eij-16000217
Ontai et al., Early multidrug treatment of SARS-CoV-2 (COVID-19) and decreased case fatality rates in Honduras, Epidemiology International Journal, doi:10.23880/eij-16000217
Jul 2021   Source   PDF  
  All Studies   Meta
Report on the nationwide implementation of multi-drug COVID-19 inpatient and outpatient treatment protocols in Honduras, showing a case fatality rate decrease from 9.33% to 2.97%. No decrease was seen in Mexico, a similar Latin American country that did not introduce multi-drug treatment protocols at that time. Decreases in COVID-19 case fatality rates in Honduras were associated with both the initial publication of the protocol and a subsequent outreach program. Both inpatient and outpatient protocols include ivermectin as one component.
Ontai et al., 25 Jul 2021, peer-reviewed, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Early Multidrug Treatment of SARS-Cov-2 (COVID-19) and Decreased Case Fatality Rates in Honduras
Early Multidrug, L Zeng, Sierra Hoffman, Valerio Pascua, Mccullough Pa, MD, MBA Sidney Ontai
Epidemiology International Journal, doi:10.23880/eij-16000217
Introduction: Within 2 months of first detection of SARS-CoV-2 in Honduras, its government promoted nationwide implementation of multidrug COVID-19 inpatient and outpatient protocols. This was associated with a case fatality rate decrease from 9.33% to 2.97%. No decrease was seen in Mexico, a similar Latin-American country that did not introduce multidrug treatment protocols at that time. Objective: The primary objective of the study was to use statistical process control to assess the likelihood that the decrease in case fatality rate in Honduras was due to chance, using Mexico as a control country. Methods: Fourteen day running average COVID-19 case fatality rates in Mexico and Honduras were used to create Shewhart control charts during the first 6 months of the epidemic. The date of implementation in Honduras of the inpatient and outpatient multidrug COVID-19 protocols were plotted on control charts, with a Mexican COVID-19 case fatality control chart as a comparison. Results: The case fatality rate for COVID-19 in Honduras dropped below the lower control limit 9 days after implementation of an inpatient multidrug inpatient protocol, from an average 9.33% case fatality rate to 5.01%. The Honduran COVID-19 case fatality rate again dropped below the 5.01% control chart limit 17 days after implementation of an outpatient multidrug protocol, to an average 2.97%, suggesting statistically significant anomalies. No control limit anomalies were seen during the same period in neighbouring Mexico. Conclusion: There was an association between both inpatient and outpatient multidrug treatment of COVID-19 and decreased fatality rates in Honduras.
Bryant, Lawrie, Dowswell, Fordham, Mitchell, Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Metaanalysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am J Ther
Choi, Bhat, Velasquez, Welch, Coronavirus in New York City
Horby, Lim, Emberson, Mafham, Bell, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Lemos, Do, Santo, Salvetti, Gilo et al., Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID), Thromb Res
Mariette, Hermine, Tharaux, Rigon, Steg, Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the Corimuno-Toci-1 Randomized Clinical Trial, JAMA Intern Med
Padgett, Spurrier, Shewhart-type charts for percentiles of strength distributions, Journal of Quality Technology, doi:10.1080/00224065.1990.11979260
Pascua, Diaz, Medina, Contreras, Mistroff, A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients, PLoS One, doi:
Perla, Provost, Parry, Little, Provost, Understanding variation in reported covid-19 death with a novel Shewhart chart application, Int J Qual Health Care
Sandhu, Tieng, Chilimuri, Franchin, A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection, Canadian Journal of Infectious Diseases and Medical Microbiology
Tardif, Bouabdallaoui, Allier, Gaudet, Shah, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Resp Med
Thor, Lundberg, Ask, Olsson, Carli, Application of statistical process control in healthcare improvement: systematic review, Qual Saf Health Care
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop